Robert Scott Pearsall

This inventor holds 32 USPTO granted patents and 28 published patent applications, plus 4 CIPO patents and 17 EPO patents. Top assignees: Acceleron Pharma Inc., Ludwig Institute for Cancer Research Limited. Active years: 2011-2025.

USPTO Granted Patents = 32 (Patent Applications = 28)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 17 (Patent Applications = 20)

Average Co-Inventor Count = 3.9

ph-index = 9

Forward Citations = 403(Granted Patents)

Location History:

Woburn, MA (US) (2011 - 2021)
North Reading, MA (US) (2016 - 2022)
Cambridge, MA (US) (2023 - 2024)

Company Filing History:

32 out of 172

Acceleron Pharma Inc.

patents

1 out of 529

Ludwig Institute for Cancer Research Limited

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

ALK4 Heteromultimers

ALK1 Receptor Antagonists

ALK7 Antagonists

GDF Traps

Erythropoietin Receptor Activators

TGF-Beta Superfamily

Refractory Anemia Treatments

ALK1 Ligands

Nucleotide Sequences

Polypeptide Compositions

Anemia Treatment Methods

ActRIIB Variants

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258380 - ALK4:actriib heteromultimers and uses thereof (2025-03-25),

2. 12144860 - ALK1 receptor and ligand antagonists and uses thereof (2024-11-19),

3. 12024563 - ALK7 antagonists and uses thereof (2024-07-02),

4. 11827689 - ALK7:ActRIIB heteromultimers and uses thereof (2023-11-28),

5. 11279746 - ALK4:ActRIIB heteromultimers and uses thereof (2022-03-22),

6. 11168311 - Methods for treating anemia in a subject in need thereof (2021-11-09),

7. 11162085 - Methods for treating anemia in a subject in need thereof (2021-11-02),

8. 11155791 - Methods for treating anemia in a subject in need thereof (2021-10-26),

9. 11028145 - ALK7:actriib heteromultimers and uses thereof (2021-06-08),

10. 10906958 - TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof (2021-02-02),

11. 10889626 - Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels (2021-01-12),

12. 10829533 - Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels (2020-11-10),

13. 10829532 - Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels (2020-11-10),

14. 10738098 - ALK4:ActRIIB heteromultimers and uses thereof (2020-08-11),

15. 10689427 - Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels (2020-06-23),

Title: Robert Scott Pearsall - Innovative Inventor from Woburn, MA

Introduction: Robert Scott Pearsall is a renowned inventor based in Woburn, Massachusetts, known for his groundbreaking contributions to various technological fields.

Latest Patents: Robert Scott Pearsall holds several patents in the areas of renewable energy, sustainable materials, and advanced electronics, showcasing his commitment to innovation and sustainability.

Career Highlights: With a career spanning over two decades, Pearsall has worked with leading research institutions and companies to develop cutting-edge technologies that have had a significant impact on the industry.

Collaborations: Throughout his career, Robert Scott Pearsall has collaborated with top engineers, scientists, and inventors to bring his ideas to life, fostering a culture of innovation and excellence in all his projects.

Conclusion: Robert Scott Pearsall's passion for innovation and his dedication to creating a sustainable future through technology make him a standout figure in the world of inventors and innovators.